Dr. Glen Boyle is Head of the Cancer Drug Mechanisms Group in the Cancer Program, at QIMR Berghofer Medical Research Institute. Boyle established his group in October 2013, and was promoted to Senior Research Fellow in February 2015. He was the recipient of the Wilson Fellowship for Skin Cancer Research, sponsored by Perpetual Trustees (2013-2016). He has been a Smart Futures Researcher-in-Residence sponsored by the Queensland Government (2011-2012) and has held NHMRC and Cancer Council Queensland Grants investigating investigating novel pathways in the formation of skin cancer and melanoma, and the development of novel anti-cancer treatments. Boyle has been investigating the molecular development of head and neck and cutaneous squamous cell carcinoma and melanoma since 1999. Boyle has a strong national, and a growing international, profile in cancer biology and novel drug discovery and characterisation. He is a molecular and cellular biologist who has developed an inducible ablation system in cell lines over a number of years, and established spontaneous metastatic human melanoma models in mice. He has wide experience in cancer research, in particular the molecular mechanisms of progression, invasion and metastasis. Boyle also has extensive experience in functional analyses of cancer cells following manipulation. He has also been involved in pre-clinical studies resulting in a product on the market, and a compound currently in Phase I trials for treatment of melanoma and head and neck cancer.
Current QIMR Berghofer appointments
- 2017 – current: QIMR Berghofer Senior Research Fellow / Group Leader, Cancer Drug Mechanisms Group.
- 2013 – 2016: Team Head, Cancer Drug Mechanisms Group, Wilson Fellow for Skin Cancer Research, Department of Cell and Molecular Biology, Cancer Program
- 2011 – 2012: Smart Futures Fellow, Senior Research Officer, Drug Discovery Group, QIMR.
- 2003 – 2010: Senior Research Officer, Drug Discovery Group, Division of Cancer and Cell Biology, QIMR.
- 1999 – 2003: Research Officer, Melanoma Genomics Group, Division of Population and Clinical Sciences, QIMR.
Current Area of Research
The Cancer Drug Mechanisms Group combines expertise in cancer biology with drug studies. The current focus is understanding the development and progression of skin and oral cavity cancers. Specifically, the molecular mechanisms involved in the progression and metastasis of melanoma, head and neck cancer, as well as cutaneous squamous cell carcinoma. These molecular mechanisms also impact on drug resistance of cancers. The identification and understanding of aberrantly regulated pathways in these cancers is crucial prior to the design or identification of suitable agents to treat the diseases.
- Discovery of a molecule in metastatic melanoma with application for detection and treatment of the disease.
- First to link mechanism of mutually exclusive expression of key transcription factors in melanoma.
- Characterisation of function of germline and somatic mutation in key melanoma transcription factor. This work was lead by Prof. Nick Hayward.
- Mechanism-of-action and efficacy studies of 2 novel anti-cancer agents, including initial publications describing the molecules. One approved for sale internationally in 2012, the other in Phase I trials beginning late 2014.
- Identification and testing of novel classes of anti-cancer agents for treatment of melanoma and head & neck SCC.
- Discovery of new markers for detection and prognosis of head & neck SCC and perineural invasion of SCC.
- 2006 – current: Australian Society for Medical Research (ASMR)
- 2006 – current: Society for Melanoma Research (SMR)
- 1996 – current: Australian Society for Biochemistry and Molecular Biology (ASBMB)
- 2013: Perpetual Foundation “Wilson Fellowship” for Skin Cancer Research
- 2011: Smart Futures Researcher-in-Residence from the Queensland Government
- 2009: Queensland Premier’s Awards for Health and Medical Research, Senior Researcher category, Runner-up
- 2008: Australian Academy of Science, Theo Murphy “High Flyers” Think Tank, Preventative health: Science and technology in the prevention and early detection of disease, Participant
- 1997: Australian Society for Biochemistry and Molecular Biology Student Poster Award, Life Science Award
- 1994 – 1997: Australian Postgraduate Award
- 1993: HECS Scholarship. Awarded by Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria
- 2000: PhD (Medicine) at the Department of Biochemisty and Molecular Biology, Monash University.
- 1993: Honours Degree Biochemistry and Molecular Biology, Monash University.
- 1990: Bachelor of Science, Monash University.